¼¼°èÀÇ ÀÚÀ²½Å°æ½ÇÁ¶Áõ ½ÃÀå º¸°í¼­(2025³â)
Dysautonomia (Autonomic Dysfunction) Global Market Report 2025
»óǰÄÚµå : 1720787
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,183,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,938,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,692,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÀÚÀ²½Å°æ½ÇÁ¶Áõ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ ±Þ¼ºÀåÀÌ Àü¸ÁµËÀÔ´Ï´Ù. 2029³â¿¡´Â CAGR 11.5%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 45¾ï 3,000¸¸ ´Þ·¯·Î ¼ºÀåÀÌ ¿¹ÃøµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È ¼ºÀåÀº ¸ÂÃãÇü ÀÇ·áÀÇ Ã¤¿ë Áõ°¡, ½Å±Ô Ä¡·á¹ý ÀÓ»ó½ÃÇè Áõ°¡, Èñ±ÍÁúȯ ¿¬±¸¿¡ ´ëÇÑ Á¤ºÎ ÀÚ±Ý Áõ°¡, ¿ø°ÝÀÇ·á ¹× ¿ø°Ý ¸ð´ÏÅ͸µ ¼Ö·ç¼Ç È®´ë, Èñ±Í ÀǾàǰ ÀÌ¿ë °¡´É¼º È®´ë µîÀÇ ¿äÀο¡ ÀÇÇÑ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ ±â°£¿¡ ¿¹»óµÇ´Â ÁÖ¿ä µ¿ÇâÀ¸·Î´Â Áø´Ü¿¡¼­ ÀΰøÁö´É ÅëÇÕ, Ç¥Àû Ä¡·á °³¹ß, ÀÚÀ²½Å°æ ¸ð´ÏÅ͸µÀ» À§ÇÑ ¿þ¾î·¯ºí µð¹ÙÀ̽º »ç¿ë, À¯ÀüÀÚ Ä¡·áÀÇ Áøº¸, ȯÀÚ Áß½ÉÀÇ Ä¡·á Á¢±Ù¹ý Çõ½Å µîÀÌ ÀÖ½À´Ï´Ù.

¸¸¼ºÁúȯÀÇ À¯º´·ü »ó½ÂÀº ÀÚÀ²½Å°æ½ÇÁ¶Áõ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¸¸¼ºÁúȯÀº 3°³¿ù ÀÌ»ó Áö¼ÓµÇ´Â Àå±âÀûÀÎ ÁúȯÀ̸ç, ±× Áõ°¡´Â °³ÀÎÀÌ ¿©·¯ ¸¸¼ºÁúȯ°ú µ¿½Ã¿¡ Áø´Ü¹Þ´Â ´ÙÁúȯ º´Á¸Áõ(multimorbidity) Áõ°¡ µîÀÇ ¿äÀΰú °ü·ÃµÇ¾î ÀÖ½À´Ï´Ù. ÀÚÀ²½Å°æ½ÇÁ¶ÁõÀº ½É¹Ú¼ö, Ç÷¾Ð, ¼ÒÈ­ µîÀÇ Áß¿äÇÑ ±â´ÉÀ» Á¶ÀýÇÏ´Â ½ÅüÀÇ ´É·ÂÀ» Àå¾ÖÇÔÀ¸·Î½á ÀÌ·¯ÇÑ Áúȯ¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, Á¾Á¾ Áõ»óÀ» ¾ÇÈ­½Ã۰í Ä¡·á¸¦ º¹ÀâÇÏ°Ô ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 10¿ù ¿µ±¹ÀÇ ±¹¹Îº¸°Ç¼­ºñ½º(National Health Service)´Â À×±Û·£µåÀÇ 1Çü ´ç´¢º´ À¯º´·üÀÌ 2020-2021³â 261,710·Ê¿¡¼­ 2021-2022³â 270,935·Ê·Î Áõ°¡ÇÏ¿© Àü³â ´ëºñ 3.5% Áõ°¡Çß´Ù°í º¸°íÇß½À´Ï´Ù. ¸¸¼ºÁúȯÀÌ º¸ÆíÈ­µÊ¿¡ µû¶ó ÀÚÀ²½Å°æ½ÇÁ¶Áõ ½ÃÀåÀÇ È®´ë°¡ ¿¹»óµË´Ï´Ù.

ÀÚ°¡¸é¿ªÁúȯ°ú ½Å°æÁúȯ Áõ°¡µµ ½ÃÀå ¼ºÀåÀÇ ¿øµ¿·ÂÀÌ µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÚ°¡¸é¿ªÁúȯ ¹× ½Å°æÁúȯÀº ¸é¿ª°è°¡ ½Ç¼ö·Î ½Å°æ°è¸¦ °ø°ÝÇÏ¿© ³ú, ô¼ö, ¸»ÃʽŰ濡 ¿°Áõ, ¼Õ»ó, ±â´ÉÀå¾Ö¸¦ ÀÏÀ¸Å°¸é¼­ ¹ßº´ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Áõ°¡´Â À¯ÀüÀû ¼ÒÀÎ, ȯ°æÀû À¯ÀÎ, ¶óÀÌÇÁ ½ºÅ¸ÀÏÀÇ º¯È­, °¨¿°, Áø´Ü ±â¼úÀÇ Çâ»ó µîÀÇ ¿äÀο¡ ÀÇÇÑ °ÍÀÔ´Ï´Ù. ¸ð±×·»ÁõÈıº, ´Ù¹ß¼º°æÈ­Áõ, ÆÄŲ½¼º´, ´Ù°èÅëÀ§ÃàÁõ(MSA) µîÀÇ Áúȯ¿¡¼­ ÀÚÀ²½Å°æ½ÇÁ¶ÁõÀÇ Á¸Àç´Â Á¾Á¾ ÀÌ·¯ÇÑ ÁúȯÀÇ Áß¿äÇÑ ÁöÇ¥°¡ µË´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 7¿ù ½ºÄÚÆ²·£µå °øÁߺ¸°Ç±¹Àº 2022³â »õ·Î ´Ù¹ß¼º °æÈ­ÁõÀ¸·Î Áø´ÜµÈ ȯÀÚ ¼ö°¡ 87.2% Áõ°¡ÇØ 491¸íÀÇ ½Å±Ô »ç·Ê°¡ º¸°íµÅ ÃÑ 6,359¸íÀÌ µÆ´Ù°í º¸°íÇß½À´Ï´Ù. ÀÚ°¡¸é¿ªÁúȯ°ú ½Å°æÁúȯÀÇ Áõ°¡¿¡ µû¶ó ÀÚÀ²½Å°æ½ÇÁ¶Áõ ½ÃÀåÀº ¾ÕÀ¸·Îµµ °è¼Ó ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ ¹× Àü·«

Á¦4Àå ½ÃÀå-°Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°ÀÇ ¿µÇâ°ú ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼® ¹× Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº° ¹× ±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ ¹× ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å· ¹× ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹® ¹× Àü·«

Á¦36Àå ºÎ·Ï

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Dysautonomia, or autonomic dysfunction, refers to a condition in which the autonomic nervous system (ANS) malfunctions, affecting involuntary bodily functions such as heart rate, blood pressure, digestion, and temperature regulation. It can be caused by various factors such as genetic predispositions, injuries, or underlying health conditions, leading to symptoms such as dizziness, fainting, and irregular heartbeats.

The primary types of dysautonomia (autonomic dysfunction) include neurogenic orthostatic hypotension (NOH), postural orthostatic tachycardia syndrome (POTS), multiple system atrophy (MSA), pure autonomic failure (PAF), and other forms. Neurogenic orthostatic hypotension occurs due to autonomic nervous system dysfunction, causing a significant drop in blood pressure when standing, which results in dizziness, lightheadedness, and fainting. Diagnosing dysautonomia involves tests such as cardiovagal and vasomotor function assessments, the thermoregulatory sweat test (TST), sympathetic skin response (SSR), and the quantitative sudomotor axon reflex test, among others. Treatment options include physical therapy, exercise therapy, counseling, and other therapeutic interventions. Medications and treatments are distributed through hospital pharmacies, online pharmacies, and retail pharmacies, with key end users being hospitals, clinics, diagnostic centers, and research institutes.

The dysautonomia (autonomic dysfunction) market research report is one of a series of new reports from The Business Research Company that provides dysautonomia (autonomic dysfunction) market statistics, including the dysautonomia (autonomic dysfunction) industry global market size, regional shares, competitors with the dysautonomia (autonomic dysfunction) market share, detailed dysautonomia (autonomic dysfunction) market segments, market trends, and opportunities, and any further data you may need to thrive in the dysautonomia (autonomic dysfunction) industry. This dysautonomia (autonomic dysfunction) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The dysautonomia (autonomic dysfunction) market size has grown rapidly in recent years. It will grow from $2.62 billion in 2024 to $2.92 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth during the historic period can be attributed to factors such as the rising prevalence of autonomic disorders, greater awareness of dysautonomia, increased healthcare spending, expanding research into neurodegenerative diseases, and growing government support for rare diseases.

The dysautonomia (autonomic dysfunction) market size is expected to see rapid growth in the next few years. It will grow to $4.53 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth during the forecast period can be attributed to factors such as the increasing adoption of personalized medicine, a rise in clinical trials for novel treatments, growing government funding for rare disease research, the expansion of telemedicine and remote monitoring solutions, and greater availability of orphan drugs. Key trends expected in this period include the integration of artificial intelligence in diagnostics, the development of targeted therapies, the use of wearable devices for autonomic monitoring, advancements in gene therapies, and innovation in patient-centric treatment approaches.

The rising prevalence of chronic diseases is expected to drive the growth of the dysautonomia (autonomic dysfunction) market. Chronic diseases are long-lasting conditions that persist for more than three months, and their increase is linked to factors such as the growing occurrence of multimorbidity, where individuals are diagnosed with multiple chronic disorders simultaneously. Dysautonomia plays a significant role in these conditions by disrupting the body's ability to regulate critical functions such as heart rate, blood pressure, and digestion, often worsening symptoms and complicating treatment. For example, in October 2023, the National Health Service in the UK reported that the prevalence of Type 1 diabetes in England rose from 261,710 cases in 2020-21 to 270,935 cases in 2021-22, marking a 3.5% increase year-over-year. As chronic diseases become more common, the dysautonomia market is expected to expand.

The growing number of autoimmune and neurological disorders is also expected to drive market growth. Autoimmune and neurological disorders occur when the immune system mistakenly attacks the nervous system, causing inflammation, damage, and dysfunction in the brain, spinal cord, or peripheral nerves. This increase is attributed to factors such as genetic predisposition, environmental triggers, lifestyle changes, infections, and better diagnostic techniques. Dysautonomia is often a key indicator of these disorders, as its presence in conditions such as Sj?gren's syndrome, multiple sclerosis, Parkinson's disease, and multiple system atrophy (MSA) helps doctors identify, monitor, and manage disease progression and create more targeted treatments. For instance, in July 2023, Public Health Scotland reported that the number of newly diagnosed multiple sclerosis patients rose by 87.2% in 2022, with 491 new cases reported, bringing the total to 6,359. As autoimmune and neurological disorders increase, the dysautonomia market is expected to continue growing.

Companies are focusing on developing new treatments using recombinant adeno-associated viruses (rAAV) to deliver therapeutic genes to target cells more effectively. rAAV is a modified virus used in gene therapy to introduce genetic material into cells without causing disease. For example, in January 2025, Tikun Therapeutics Inc., a U.S.-based biotechnology company, received FDA approval for Orphan Drug and Rare Pediatric Disease Designations for its gene therapy treatments rAAV2-U1a-hELP1, designed for optic neuropathy in familial dysautonomia, and BPN-36964, a small molecule splicing modulator for systemic FD treatment. These therapies aim to address the genetic causes of familial dysautonomia, offering long-term benefits beyond symptomatic treatment.

Major players in the dysautonomia (autonomic dysfunction) market are Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Cadila Healthcare Limited (Zydus Cadila), Lupin Limited, Nemours Children's Health Delaware, Alnylam Pharmaceuticals Inc., Biohaven Pharmaceuticals Holding Company Ltd., Aurora Health Care Inc., Camber Pharmaceuticals Inc., Theravance Biopharma Inc., Tocris Bioscience a subsidiary of Bio-Techne Corporation, Celltex Therapeutics Corporation, DyAnsys Inc., Axplora Inc., MODAG GmbH, Inhibikase Therapeutics Inc., Mylan Pharmaceuticals Private Limited, Chelsea Therapeutics International Ltd.

North America was the largest region in the dysautonomia (autonomic dysfunction) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dysautonomia (autonomic dysfunction) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the dysautonomia (autonomic dysfunction) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The dysautonomia (autonomic dysfunction) market consists of revenues earned by entities by providing services such as pharmaceutical treatment, radiation therapy, diagnostic services, and surgical interventions. The market value includes the value of related goods sold by the service provider or included within the service offering. The dysautonomia (autonomic dysfunction) market also includes sales of diagnostic tools, intravenous therapies, neurostimulatory devices, compression garments, and electrolyte supplements. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Dysautonomia (Autonomic Dysfunction) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on dysautonomia (autonomic dysfunction) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for dysautonomia (autonomic dysfunction) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dysautonomia (autonomic dysfunction) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Dysautonomia (Autonomic Dysfunction) Market Characteristics

3. Dysautonomia (Autonomic Dysfunction) Market Trends And Strategies

4. Dysautonomia (Autonomic Dysfunction) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Dysautonomia (Autonomic Dysfunction) Growth Analysis And Strategic Analysis Framework

6. Dysautonomia (Autonomic Dysfunction) Market Segmentation

7. Dysautonomia (Autonomic Dysfunction) Market Regional And Country Analysis

8. Asia-Pacific Dysautonomia (Autonomic Dysfunction) Market

9. China Dysautonomia (Autonomic Dysfunction) Market

10. India Dysautonomia (Autonomic Dysfunction) Market

11. Japan Dysautonomia (Autonomic Dysfunction) Market

12. Australia Dysautonomia (Autonomic Dysfunction) Market

13. Indonesia Dysautonomia (Autonomic Dysfunction) Market

14. South Korea Dysautonomia (Autonomic Dysfunction) Market

15. Western Europe Dysautonomia (Autonomic Dysfunction) Market

16. UK Dysautonomia (Autonomic Dysfunction) Market

17. Germany Dysautonomia (Autonomic Dysfunction) Market

18. France Dysautonomia (Autonomic Dysfunction) Market

19. Italy Dysautonomia (Autonomic Dysfunction) Market

20. Spain Dysautonomia (Autonomic Dysfunction) Market

21. Eastern Europe Dysautonomia (Autonomic Dysfunction) Market

22. Russia Dysautonomia (Autonomic Dysfunction) Market

23. North America Dysautonomia (Autonomic Dysfunction) Market

24. USA Dysautonomia (Autonomic Dysfunction) Market

25. Canada Dysautonomia (Autonomic Dysfunction) Market

26. South America Dysautonomia (Autonomic Dysfunction) Market

27. Brazil Dysautonomia (Autonomic Dysfunction) Market

28. Middle East Dysautonomia (Autonomic Dysfunction) Market

29. Africa Dysautonomia (Autonomic Dysfunction) Market

30. Dysautonomia (Autonomic Dysfunction) Market Competitive Landscape And Company Profiles

31. Dysautonomia (Autonomic Dysfunction) Market Other Major And Innovative Companies

32. Global Dysautonomia (Autonomic Dysfunction) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Dysautonomia (Autonomic Dysfunction) Market

34. Recent Developments In The Dysautonomia (Autonomic Dysfunction) Market

35. Dysautonomia (Autonomic Dysfunction) Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â